3-(β-D-glucopyranosyloxy)-5-methyl-4-([4-(pyridin-2-yl)-phenyl]methyl)-1H-pyrazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-(β-D-glucopyranosyloxy)-5-methyl-4-([4-(pyridin-2-yl)-phenyl]methyl)-1H-pyrazole
• 英文别名: 3-(beta-D-Glucopyranosyloxy)-5-methyl-4-{[4-(pyridin-2-yl)phenyl]methyl}-1H-pyrazole；(2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[[5-methyl-4-[(4-pyridin-2-ylphenyl)methyl]-1H-pyrazol-3-yl]oxy]oxane-3,4,5-triol
• 化学式: C₂₂H₂₅N₃O₆
• 分子量: 427.457
• InChiKey: FNCGVVLIBPUUDV-JPVHLGFFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  141
• 氢给体数：
  5
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  2-(4-甲基苯基)吡啶 在 N-氯代丁二酰亚胺 、 偶氮二异丁腈 作用下， 以 四氯化碳 为溶剂， 反应 5.0h， 生成 3-(β-D-glucopyranosyloxy)-5-methyl-4-([4-(pyridin-2-yl)-phenyl]methyl)-1H-pyrazole
  参考文献：
  名称：

  GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND MEDICINAL USE THEREOF

  摘要：

  公开号：

  EP1364957B1

文献信息

• Glucopyranosyloxypyrazole derivatives and medicinal use thereof
  申请人：Nishimura Toshihiro

  公开号：US20060142209A1

  公开（公告）日：2006-06-29

  The present invention provides glucopyranosyloxypyrazole derivatives represented by the general formula: wherein one of Q and T represents a group represented by the general formula: while the other represents a lower alkyl group or a halo(lower alkyl) group; R 1 represents a hydrogen atom, an optionally substituted lower alkyl group, a lower alkenyl group, a cyclic lower alkyl group, etc.; R 2 represents a hydrogen atom, an optionally substituted lower alkyl group, a lower alkoxy group, a lower alkenyl group, a cyclic lower alkyl group, a cyclic lower alkoxy group, etc., which exert an excellent inhibitory activity in human SGLT2, and therefore are useful as drugs for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, pharmaceutically acceptable salts thereof or prodrugs thereof, production intermediates thereof and pharmaceutical uses thereof.

  本发明提供一种由下式表示的葡萄糖吡唑衍生物：其中Q和T中的一个表示由下式表示的基团：而另一个表示较低的烷基或卤代（较低的烷基）基团；R1表示氢原子、可选地取代的较低烷基基团、较低烯基基团、环状较低烷基基团等；R2表示氢原子、可选地取代的较低烷基基团、较低烷氧基基团、较低烯基基团、环状较低烷基基团、环状较低烷氧基基团等，这些化合物在人类SGLT2中表现出优异的抑制活性，因此可用作预防或治疗与高血糖相关的疾病，如糖尿病、糖尿病并发症或肥胖症的药物，其药学上可接受的盐或前药，其生产中间体以及其制药用途。
• Glycopyranosyloxypyrazole derivatives and medicinal use thereof
  申请人：——

  公开号：US20040132669A1

  公开（公告）日：2004-07-08

  The present invention provides glucopyranosyloxypyrazole derivatives represented by the general formula: 1 wherein one of Q and T represents a group represented by the general formula: 2 while the other represents a lower alkyl group or a halo(lower alkyl) group; R 1 represents a hydrogen atom, an optionally substituted lower alkyl group, a lower alkenyl group, a cyclic lower alkyl group, etc.; R 2 represents a hydrogen atom, an optionally substituted lower alkyl group, a lower alkoxy group, a lower alkenyl group, a cyclic lower alkyl group, a cyclic lower alkoxy group, etc., which exert an excellent inhibitory activity in human SGLT2, and therefore are useful as drugs for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, pharmaceutically acceptable salts thereof or prodrugs thereof, production intermediates thereof and pharmaceutical uses thereof.

  本发明提供了一种由通式1表示的葡萄糖吡唑衍生物，其中Q和T中的一个表示由通式2表示的基团，而另一个表示较低的烷基基团或卤代（较低的烷基）基团；R1表示氢原子、可选取代的较低烷基基团、较低烯基基团、环状较低烷基基团等；R2表示氢原子、可选取代的较低烷基基团、较低烷氧基团、较低烯基基团、环状较低烷基基团、环状较低烷氧基团等。这些衍生物在人类SGLT2中具有出色的抑制活性，因此可用作预防或治疗与高血糖相关的疾病，如糖尿病、糖尿病并发症或肥胖症的药物，以及其药学上可接受的盐或前药、生产中间体及其制药用途。
• US7087579B2
  申请人：——

  公开号：US7087579B2

  公开（公告）日：2006-08-08
• US7189702B2
  申请人：——

  公开号：US7189702B2

  公开（公告）日：2007-03-13
• GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND MEDICINAL USE THEREOF
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：EP1364957B1

  公开（公告）日：2008-12-31